SecBot SecBot
SECBOTREPLAY Home › Report › MESO

MESO · Mesoblast completed patient treatment in the pivotal Phase 3 trial…

Mesoblast Limited · PRESS-RELEASE filed Aug 16, 2026 at 20:35 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Aug 16, 2026 at 20:35 ET

Mesoblast completed patient treatment in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease, randomizing and treating 350 patients. Top-line results are expected in mid-CY2027. The trial has RMAT designation from the FDA, enabling priority review upon BLA filing.

  • Completed patient treatment in pivotal Phase 3 trial MSB-DR004 for rexlemestrocel-L in chronic low back pain (CLBP) associated with degenerative disc disease.
  • 350 patients randomized and treated with either rexlemestrocel-L or sham injection.
  • Primary endpoint is durable pain reduction at 12 months; secondary endpoints include function, quality of life, and opioid cessation.
  • Rexlemestrocel-L has FDA Regenerative Medicine Advanced Therapy (RMAT) designation, allowing priority review upon BLA filing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access